Market Overview
Psoriasis is a chronic autoimmune disease that manifests as thickened, inflamed patches of skin. While its exact cause remains uncertain, it is widely recognized as an immune-mediated condition triggered by genetic and environmental factors. Affecting over 125 million people globally, psoriasis can lead to serious complications, including psoriatic arthritis, depression, and cardiovascular issues if left untreated.
Global Psoriasis Drug Market size and share is currently valued at USD 29.5 billion in 2024 and is anticipated to generate an estimated revenue of USD 56.96 billion by 2034, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 10.8% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2025 - 2034
A paradigm shift from symptomatic relief through topical treatments to disease-modifying biologic therapies and systemic medications is transforming patient outcomes. Pharmaceutical companies and healthcare systems alike are increasingly investing in long-term remission strategies, targeting the underlying immunological pathways involved in psoriasis.
Market Segmentation
The psoriasis drug market is segmented by drug class, route of administration, type, and distribution channel.
1. By Drug Class
Topical Treatments
These include corticosteroids, vitamin D analogs, and calcineurin inhibitors. They are primarily used for mild to moderate psoriasis and remain the first-line treatment in many cases.Systemic Medications
Encompass oral drugs like methotrexate, cyclosporine, and the newer class of small molecule inhibitors. These are used in moderate to severe cases and offer more comprehensive immunomodulatory effects.Biologic Therapies
The fastest-growing segment, biologics such as TNF inhibitors, IL-17, IL-12/23, and IL-23 inhibitors target specific immune system pathways, offering higher efficacy and fewer side effects.Others
Includes phototherapy drugs and combination therapies, which are gaining traction as adjunct treatments.
2. By Route of Administration
Oral
Systemic medications taken orally offer convenience and are often prescribed when topical therapies are insufficient.Injectable
Biologic drugs are typically administered via injection or infusion, requiring medical supervision in most cases.Topical
Applied directly to the skin, these are the most accessible and affordable options, particularly in developing markets.
3. By Type
Prescription Drugs
Dominating the market, these include both biologics and traditional systemics, often covered by insurance or national healthcare programs.Over-the-Counter (OTC) Drugs
Topical corticosteroids and moisturizers that help manage mild symptoms are available without a prescription.
4. By Distribution Channel
Hospital Pharmacies
Often the primary point for dispensing biologics and systemic drugs requiring administration by healthcare professionals.Retail Pharmacies
Play a key role in the distribution of topical and oral therapies.Online Pharmacies
This segment is growing due to convenience, increased digital adoption, and better accessibility in remote areas.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/global-psoriasis-drug-market
Regional Analysis
North America
North America leads the global market, contributing over 40% of total revenue in 2024. High disease prevalence, favorable reimbursement policies, and widespread adoption of biologic therapies drive this dominance. The United States, in particular, benefits from a strong pipeline of drug candidates and robust healthcare infrastructure.
Europe
Europe holds the second-largest market share, with countries like Germany, France, and the UK implementing early screening programs and facilitating access to new biologics through public healthcare systems. The region also benefits from regulatory efficiency through the European Medicines Agency (EMA).
Asia-Pacific
The Asia-Pacific region is anticipated to grow at the highest CAGR of 7.4% during the forecast period. Rising healthcare investments, growing awareness about autoimmune diseases, and the increasing presence of global pharmaceutical players are key factors. Japan and China are at the forefront, while India is showing promising growth due to government health initiatives and generic drug manufacturing.
Latin America
Countries like Brazil and Mexico are emerging markets, showing increased demand for both prescription and OTC treatments. Expansion of insurance coverage and improved diagnostic capabilities are fueling this regional growth.
Middle East Africa
While market penetration remains low, the region shows potential due to gradual improvements in healthcare access and awareness campaigns. International partnerships and donor-funded health programs are playing a crucial role.
Key Companies in the Psoriasis Drug Market
The competitive landscape is characterized by strategic RD investments, regulatory approvals, and biosimilar development. Major pharmaceutical players are focusing on expanding their biologic portfolios while also exploring new small molecule treatments.
AbbVie Inc.
A leader in the psoriasis space, AbbVie’s Skyrizi (risankizumab) and legacy drug Humira (adalimumab) have significantly shaped the biologics market. Skyrizi has become a preferred treatment due to its strong efficacy and safety profile.
Amgen Inc.
Amgen markets Enbrel (etanercept), one of the earliest TNF inhibitors approved for psoriasis. The company continues to invest in biosimilar development to retain market relevance.
Johnson Johnson (Janssen Pharmaceuticals)
Through its subsidiary Janssen, the company offers Tremfya (guselkumab), which targets IL-23. It is considered one of the most effective therapies with a durable response.
Novartis AG
Novartis's Cosentyx (secukinumab), an IL-17A inhibitor, is a blockbuster biologic used worldwide. The drug has a strong real-world data record and is approved in over 80 countries.
Eli Lilly and Company
Lilly’s Taltz (ixekizumab) is an IL-17A inhibitor competing directly with Cosentyx. Its rapid onset and sustained clearance rates make it a key player in the moderate to severe psoriasis segment.
Pfizer Inc.
Pfizer is expanding its reach with Cibinqo (abrocitinib) and other JAK inhibitors, as well as topical therapies for less severe disease forms. The company is also exploring TYK2 inhibition as a next-gen treatment approach.
Sun Pharmaceutical Industries
This India-based pharmaceutical giant is a strong player in the generic psoriasis drug segment. Its acquisition of Opiates and expanding portfolio in dermatology give it a strategic edge in cost-sensitive markets.
Other Notable Companies:
Bristol Myers Squibb
UCB Pharma
Biogen
Dermavant Sciences
Leo Pharma
Market Outlook
The future of the psoriasis drug market lies in innovation, affordability, and personalized care. As biologic therapies become more targeted and systemic medications gain improved safety profiles, long-term disease management will become more effective and accessible.
Digital health integration, including apps for symptom tracking and remote consultations, is likely to play a significant role in improving patient adherence and monitoring. Additionally, with more biosimilars entering the market, pricing pressure on originator biologics will increase, potentially improving access in emerging markets.
Conclusion
The global psoriasis drug market is undergoing a transformative phase driven by biologic innovation, the rise of autoimmune diseases, and expanding access to systemic medications. While challenges such as high costs and access disparities persist, collaborative efforts between governments, healthcare providers, and pharmaceutical companies are fostering a more inclusive and effective treatment environment. As the market grows steadily, it promises better outcomes and improved quality of life for millions living with this chronic condition.
More Trending Latest Reports By Polaris Market Research:
Rare Disease Genetic Testing Market
